News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
US: Growth normalizes as Iran shock fades – TD Securities
FXStreet·2026/04/27 21:12
XCX (XelebProtocol) fluctuated 47.8% in 24 hours: surge in trading volume drives short-term rebound
Bitget Pulse·2026/04/27 21:08
Fed Confirms What Tech Developers Have Feared for Two Years
Decrypt·2026/04/27 20:07
ESIM (Depinsim) fluctuated by 205.7% in 24 hours: Trading volume surged 797%, driving price volatility
Bitget Pulse·2026/04/27 19:46
B2 (BSquaredNetwork) fluctuated by 55.7% in 24 hours: Trading volume surged 136%, causing intense volatility
Bitget Pulse·2026/04/27 19:19
Fed: Policy on hold as Iran shock lingers – TD Securities
FXStreet·2026/04/27 18:48
Perle (PRL) 24-Hour Price Fluctuation of 95.5%: Upbit Listing Announcement Drives Speculative Surge in Korean Market
Bitget Pulse·2026/04/27 18:33
BoJ: Cautious stance and inflation guidance in focus – Rabobank
FXStreet·2026/04/27 18:18
NOT (Notcoin) fluctuates 73.8% in 24 hours: Trading volume surges 238.5%, causing intense volatility
Bitget Pulse·2026/04/27 18:02
Flash
11:41
SK Hynix rumored to launch a shareholder return plan worth hundreds of trillions of won, official response: The specific scale has never been discussed.SK Hynix responded to Jiemian News stating that it is "exploring various options to enhance shareholder value, but the company has never discussed specific details such as the scale of shareholder returns mentioned in the relevant reports." Previously, The Korea Economic Daily reported that SK Hynix planned to launch an ultra-large shareholder return policy worth 100 trillion Korean won in the fourth quarter of this year, with specific measures including share buybacks and cash dividends. This move was interpreted by outsiders as a major strategic bet by SK Group Chairman Chey Tae-won, aiming to enhance the company’s position and valuation in the global capital market through large-scale shareholder returns.
11:40
Moderna, Inc. recently revealed that the company is actively planning its future product pipeline, and it is expected that as many as three new vaccine products may be launched between 2027 and 2028.These potential new products include a combined vaccine that protects against both influenza and COVID-19, an updated vaccine for seasonal influenza, and a new vaccine designed to prevent norovirus infection. This plan highlights Moderna’s ongoing expansion and in-depth application of its mRNA technology platform. The company is committed to extending its core mRNA research and development capabilities from the successful response to the COVID-19 pandemic to a broader range of respiratory and even gastrointestinal infectious diseases. If the combined influenza and COVID-19 vaccine is successfully launched, it could simplify public health immunization procedures and provide people with more convenient and comprehensive protection options. The development of a norovirus vaccine marks an important step for the company into a new field of disease prevention.Market analysts have pointed out that if this product pipeline plan progresses smoothly, it could open up new growth opportunities for Moderna in the coming years and strengthen its leading position in the global biotechnology and vaccine sectors. Investors are closely monitoring the progress of these research and development projects as well as their commercialization prospects.
11:40
SK Hynix Denies Rumors of 'Trillion Won Shareholder Return Plan': Never Discussed Specific ScaleBlockBeats News, June 16th - According to Jiemian News, on the evening of June 16th, regarding the market rumor of "SK Hynix's Plan for Trillion KRW Shareholder Return," it was revealed that the rumored scale of the huge return is not accurate.
SK Hynix stated that it is "exploring various options to enhance shareholder value, but the company has never discussed specific details such as the scale of shareholder return mentioned in the report."
News